Goldman Sachs initiated coverage of HealthEquity (HQY) with a Neutral rating and $108 price target The firm says its thesis on HealthEquity is balanced by a constructive view on the company’s forward earnings outlook and a clear path to achieving long-term earnings targets with what it sees as a balanced risk/reward based on valuation.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HQY: